Droxinavir

Droxinavir

SCHEMBL8170296

CNCC(=O)NC(C(=O)NC(Cc1ccccc1)C(O)CN(CCC(C)C)C(=O)NC(C)(C)C)C(C)(C)C

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 11/20 0.42
PSEN2 P49810 11/20 0.42
APH1B Q8WW43 11/20 0.42
NCSTN Q92542 11/20 0.42
APH1A Q96BI3 11/20 0.42
PSENEN Q9NZ42 11/20 0.42
MMP2 P08253 4/20 0.41
MMP3 P08254 2/20 0.41
CTSD P07339 1/20 0.41
MLNR O43193 1/20 0.41
NR1I2 O75469 1/20 0.41
SLCO2B1 O94956 1/20 0.41
ABCB11 O95342 1/20 0.41
ABCB1 P08183 1/20 0.41
UGT1A1 P22309 1/20 0.41
CCKAR P32238 1/20 0.41
OPRK1 P41145 1/20 0.41
GHSR Q92847 1/20 0.41
SLCO1B3 Q9NPD5 1/20 0.41
ABCG2 Q9UNQ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Droxinavir SCHEMBL668267 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL12510780 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL14613663 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL668266 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL14044444 1.00 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
Droxinavir SCHEMBL29636917 0.99 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8602994 0.92 PSEN1 (0.39) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL7402349 0.91 PSEN1 (0.48) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6227028 0.89 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL8570558 0.89 PSEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9107956-B2 Oligomer-protease inhibitor conjugates NEKTAR THERAPEUTICS (US) 2015-08-18 US disclosed
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2014-02-13 US disclosed
EP-2522367-A1 Oligomer-protease inhibitor conjugates Nektar Therapeutics (US) 2012-11-14 EP disclosed
US-20120108501-A1 Protease Inhibitors NEKTAR THERAPEUTICS (US) 2012-05-03 US disclosed
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates NEKTAR THERAPEUTICS (US) 2011-11-03 US disclosed
WO-2010144869-A2 PROTEASE INHIBITORS NEKTAR THERAPEUTICS (US) 2010-12-16 WO disclosed
WO-2008112289-A2 OLIGOMER-PROTEASE INHIBITOR CONJUGATES NEKTAR THERAPEUTICS (US) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108501-A1 Protease Inhibitors DNPEP, ADAM17, PREP PSEN1 245/4885PSEN2 387/4885APH1B 197/4885
US-20140045770-A1 OLIGOMER-PROTEASE INHIBITOR CONJUGATES DNPEP, ADAM17, SERPINB1 PSEN1 741/4885PSEN2 1181/4885APH1B 250/4885
US-20110269677-A1 Oligomer-Protease Inhibitor Conjugates ADAM17, DNPEP, SERPINB1 PSEN1 771/4885PSEN2 1324/4885APH1B 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.